Research progress of PCSK9 inhibitors in the treatment of dyslipidemia associated with HIV infection
The level of the preprotein convertase chymotrypsin 9(PCSK9)is typically elevated in patients with HIV/AIDS and is correlated with multiple cardiovascular risk factors.The use of PCSK9 inhibitors has been demonstrated to result in a significant reduction in low-density lipoprotein cholesterol levels in patients living with HIV/AIDS(PLWHA),while also improving coronary endothelial function and reducing the risk of cardiovascular events.The efficacy and safety of PCSK9 inhibitors in PLWHA have been confirmed in both clinical trials and real-world research.This article reviews the biological properties of PCSK9,its role in HIV infection,as well as the application and research progress of PCSK9 inhibitors in clinical therapy to inform the use of PCSK9 inhibitors in the lipid management of PLWHA.
NETL
NSTL
万方数据
